Surmodics (SRDX) Revenue & Revenue Breakdown
Surmodics Revenue Highlights
Latest Revenue (Y)
$132.58M
Latest Revenue (Q)
$30.34M
Main Segment (Y)
Royalty
Surmodics Revenue by Period
Surmodics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-09-30 | $132.58M | 32.65% |
| 2022-09-30 | $99.95M | -4.93% |
| 2021-09-30 | $105.14M | 10.83% |
| 2020-09-30 | $94.86M | -5.21% |
| 2019-09-30 | $100.08M | 23.04% |
| 2018-09-30 | $81.34M | 11.25% |
| 2017-09-30 | $73.11M | 2.45% |
| 2016-09-30 | $71.37M | 15.30% |
| 2015-09-30 | $61.90M | 7.76% |
| 2014-09-30 | $57.44M | 2.33% |
| 2013-09-30 | $56.13M | 8.10% |
| 2012-09-30 | $51.93M | -23.39% |
| 2011-09-30 | $67.78M | -3.03% |
| 2010-09-30 | $69.90M | -42.49% |
| 2009-09-30 | $121.53M | 25.23% |
| 2008-09-30 | $97.05M | 32.65% |
| 2007-09-30 | $73.16M | 4.69% |
| 2006-09-30 | $69.88M | 12.03% |
| 2005-09-30 | $62.38M | 25.42% |
| 2004-09-30 | $49.74M | 15.05% |
| 2003-09-30 | $43.23M | 46.61% |
| 2002-09-30 | $29.49M | 29.94% |
| 2001-09-30 | $22.69M | 24.15% |
| 2000-09-30 | $18.28M | 35.40% |
| 1999-09-30 | $13.50M | 37.76% |
| 1998-09-30 | $9.80M | - |
Surmodics generated $132.58M in revenue during NA 2023, up 32.65% compared to the previous quarter, and up 163.01% compared to the same period a year ago.
Surmodics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $30.34M | -5.06% |
| 2024-03-31 | $31.96M | 4.60% |
| 2023-12-31 | $30.55M | 9.23% |
| 2023-09-30 | $27.97M | -46.71% |
| 2023-06-30 | $52.48M | 92.97% |
| 2023-03-31 | $27.20M | 9.08% |
| 2022-12-31 | $24.93M | -4.06% |
| 2022-09-30 | $25.99M | 4.56% |
| 2022-06-30 | $24.85M | -4.80% |
| 2022-03-31 | $26.11M | 13.49% |
| 2021-12-31 | $23.00M | -4.04% |
| 2021-09-30 | $23.97M | 0.41% |
| 2021-06-30 | $23.87M | -31.78% |
| 2021-03-31 | $34.99M | 56.95% |
| 2020-12-31 | $22.30M | -1.09% |
| 2020-09-30 | $22.54M | -16.14% |
| 2020-06-30 | $26.88M | 17.79% |
| 2020-03-31 | $22.82M | 0.91% |
| 2019-12-31 | $22.62M | -26.61% |
| 2019-09-30 | $30.82M | 26.59% |
| 2019-06-30 | $24.34M | 7.36% |
| 2019-03-31 | $22.68M | 1.96% |
| 2018-12-31 | $22.24M | -3.46% |
| 2018-09-30 | $23.04M | 3.65% |
| 2018-06-30 | $22.23M | 16.63% |
| 2018-03-31 | $19.06M | 12.02% |
| 2017-12-31 | $17.01M | -15.18% |
| 2017-09-30 | $20.06M | 12.75% |
| 2017-06-30 | $17.79M | 1.64% |
| 2017-03-31 | $17.50M | -1.45% |
| 2016-12-31 | $17.76M | -2.16% |
| 2016-09-30 | $18.15M | -9.10% |
| 2016-06-30 | $19.97M | 19.60% |
| 2016-03-31 | $16.70M | 0.96% |
| 2015-12-31 | $16.54M | -4.73% |
| 2015-09-30 | $17.36M | 9.11% |
| 2015-06-30 | $15.91M | 10.40% |
| 2015-03-31 | $14.41M | 1.48% |
| 2014-12-31 | $14.21M | -7.37% |
| 2014-09-30 | $15.34M | 4.93% |
| 2014-06-30 | $14.62M | 7.44% |
| 2014-03-31 | $13.60M | -2.01% |
| 2013-12-31 | $13.88M | -2.90% |
| 2013-09-30 | $14.30M | 0.06% |
| 2013-06-30 | $14.29M | 4.34% |
| 2013-03-31 | $13.70M | -1.13% |
| 2012-12-31 | $13.85M | 0.06% |
| 2012-09-30 | $13.84M | -0.83% |
| 2012-06-30 | $13.96M | 14.32% |
| 2012-03-31 | $12.21M | 2.47% |
| 2011-12-31 | $11.92M | -30.53% |
| 2011-09-30 | $17.15M | -4.54% |
| 2011-06-30 | $17.97M | 2.70% |
| 2011-03-31 | $17.49M | 15.33% |
| 2010-12-31 | $15.17M | -2.45% |
| 2010-09-30 | $15.55M | -16.44% |
| 2010-06-30 | $18.61M | 1.35% |
| 2010-03-31 | $18.36M | 5.63% |
| 2009-12-31 | $17.38M | -9.51% |
| 2009-09-30 | $19.21M | 5.61% |
| 2009-06-30 | $18.19M | -13.09% |
| 2009-03-31 | $20.93M | -66.90% |
| 2008-12-31 | $63.22M | 172.03% |
| 2008-09-30 | $23.24M | -4.27% |
| 2008-06-30 | $24.28M | -5.57% |
| 2008-03-31 | $25.71M | - |
Surmodics generated $30.34M in revenue during Q3 2024, up -5.06% compared to the previous quarter, and up 111.56% compared to the same period a year ago.
Surmodics Revenue Breakdown
Surmodics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Sep 23 | Sep 22 | Sep 21 | Sep 20 | Sep 19 |
|---|---|---|---|---|---|
| Royalty | $62.40M | $36.25M | $47.06M | $40.63M | $48.46M |
| Research Development And Other | $9.57M | $9.08M | $11.60M | $9.91M | $11.40M |
| Product | $60.61M | $54.62M | $46.48M | $44.32M | $40.22M |
Surmodics's latest annual revenue breakdown by segment (product or service), as of Sep 23: Royalty (47.06%), Product (45.72%), and Research Development And Other (7.22%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $17.56M | $18.10M | $18.83M | $15.36M | $15.67M | $15.35M | $14.23M | $14.39M | $13.92M | $13.96M | $12.34M | $12.51M | $12.08M | $11.78M | $10.10M | $10.59M | $11.99M | $11.77M | $9.97M | $10.71M |
| Royalty | $10.46M | $11.41M | $9.18M | $10.05M | $34.15M | $9.43M | $8.77M | $9.51M | $8.79M | $9.84M | $8.10M | $8.87M | $8.80M | $20.05M | $9.33M | $9.87M | $12.40M | $8.22M | $10.15M | $16.81M |
| Research Development And Other | $2.32M | $2.45M | $2.55M | $2.56M | $2.66M | $2.42M | $1.93M | $2.08M | $2.14M | $2.30M | $2.56M | $2.59M | $2.99M | $3.16M | $2.86M | $2.09M | $2.50M | $2.83M | $2.49M | $3.30M |
Surmodics's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Product (57.88%), Royalty (34.47%), and Research Development And Other (7.65%).
Surmodics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ITGR | Integer | $1.60B | $753.01M |
| CNMD | CONMED | $1.24B | $332.10M |
| LIVN | LivaNova | $1.15B | $318.60M |
| INGN | Inogen | $315.66M | $88.77M |
| FNA | Paragon 28 | $216.39M | $61.02M |
| ANIK | Anika Therapeutics | $166.66M | $41.92M |
| AXGN | AxoGen | $159.01M | $47.91M |
| KIDS | OrthoPediatrics | $148.73M | $52.80M |
| SIBN | SI-BONE | $138.89M | $39.97M |
| SRDX | Surmodics | $132.58M | $30.34M |
| SGHT | Sight Sciences | $81.06M | $21.37M |
| LUNG | Pulmonx | $68.67M | $20.78M |
| NPCE | NeuroPace | $65.42M | $18.12M |
| APYX | Apyx Medical | $52.35M | $12.15M |
| OSA | ProSomnus | $27.65M | $7.46M |
| OFIX | Orthofix Medical | $100.00K | $198.62M |
SRDX Revenue FAQ
What is Surmodics’s yearly revenue?
Surmodics's yearly revenue for 2023 was $132.58M, representing an increase of 32.65% compared to 2022. The company's yearly revenue for 2022 was $99.95M, representing a decrease of -4.93% compared to 2021. SRDX's yearly revenue for 2021 was $105.14M, representing an increase of 10.83% compared to 2020.
What is Surmodics’s quarterly revenue?
Surmodics's quarterly revenue for Q3 2024 was $30.34M, a -5.06% decrease from the previous quarter (Q2 2024), and a -42.19% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $31.96M, a 4.60% increase from the previous quarter (Q1 2024), and a 17.50% increase year-over-year (Q2 2023). SRDX's quarterly revenue for Q1 2024 was $30.55M, a 9.23% increase from the previous quarter (Q4 2023), and a 22.54% increase year-over-year (Q1 2023).
What is Surmodics’s revenue growth rate?
Surmodics's revenue growth rate for the last 3 years (2021-2023) was 26.11%, and for the last 5 years (2019-2023) was 32.48%.
What are Surmodics’s revenue streams?
Surmodics's revenue streams in p 23 are Royalty, Research Development And Other, and Product. Royalty generated $62.4M in revenue, accounting 47.06% of the company's total revenue, up 72.14% year-over-year. Research Development And Other generated $9.57M in revenue, accounting 7.22% of the company's total revenue, up 5.40% year-over-year. Product generated $60.61M in revenue, accounting 45.72% of the company's total revenue, up 10.97% year-over-year.
What is Surmodics’s main source of revenue?
For the fiscal year ending Sep 23, the largest source of revenue of Surmodics was Royalty. This segment made a revenue of $62.4M, representing 47.06% of the company's total revenue.